bearish
Sipai Health Technology (314.HK) - Unjustified Valuation and Problematic Business Model
261 Views29 Mar 2023 09:15
The sustainability/stability of Sipai’s performance/growth potential is worrying. Weak profitability make Sipai hard to be breakeven.High valuation is hard to sustain due to problematic business model
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- MedSci Healthcare Holdings (2415.HK) - Lack of Control over Core Resources Is a Critical Pain Point28 Sep 2023
- Sipai Health Technology (314.HK) - Valuation Has Collapsed, but a Reversal Is Not yet in Sight27 Sep 2023
- Sipai Health Technology (314.HK) - Unjustified Valuation and Problematic Business Model29 Mar 2023
- CanSino Biologics (6185.HK) 2022 Results - It Is Time to Reassess CanSino and Its Future Prospects29 Mar 2023
- Ping An Healthcare and Technology Company Limited (1833.HK)- To Turn Things Around or to Fail Again?15 Mar 2023
- JD Health (6618.HK) - It's Time to Reassess the Business Prospects and Valuation09 Mar 2023
x